A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

Filip Janku,Gopa Iyer,Anna Spreafico,Noboru Yamamoto,Yung-Jue Bang,Elena Elez,Maja J.A. de Jonge,Harry J.M. Groen,Frederik Marmé,Kathrin Gollmer,Annie St-Pierre,Maritza Melendez,Anna Mais,Heidi Nauwelaerts,Uz Stammberger,Reinhard Dummer

A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

2018

Filip Janku
Gopa Iyer
Anna Spreafico
Noboru Yamamoto
Yung-Jue Bang
Elena Elez
Maja J.A. de Jonge
Harry J.M. Groen
Frederik Marmé
Kathrin Gollmer
Annie St-Pierre
Maritza Melendez
Anna Mais
Heidi Nauwelaerts
Uz Stammberger
Reinhard Dummer

2586Background: CRAF is a key mediator of oncogenic mitogen-activated protein kinase (MAPK) pathway reactivation following MEK or BRAF inhibition. LXH254 is a BRAF and CRAF inhibitor with antitumor...

Keywords:

Protein kinase A
MAPK/ERK pathway
Cancer research
Pathology
Mediator
Medicine
in patient
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations